Company intelligence / Profile preview

Jon Harrison

Dallas, Texas, United Statesarctic.gov ↗

Ownership: Private
Development stage: Other

Overview

Vaxxinity has developed UB-612, a multitope protein/synthetic peptide COVID vaccine with broad immune response and practical storage requirements. The company also has a pipeline targeting chronic diseases using its proprietary platform. Recent clinical results include successful first-phase trials in Parkinson's and ongoing late-stage trials in COVID

Therapeutic areas: CardiovascularNeurologyInfectious Diseases
Modalities: Synthetic peptide vaccineProtein vaccine
Industry: Biotech

Partnerships

UBI Asia (clinical development)Aurobindo Pharma (India trial partner)Maersk (logistics)

Beyond the preview

Go deeper on Jon Harrison.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jon Harrison.

Explore the full profile